Blog
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial | Nature Medicine
Researchers have reported promising results in a Phase I/II trial
Researchers have reported promising results in a Phase I/II trial
The CD19-directed, non-viral, PD-1 locus-specific, CRISPR-based integrated CAR T cell
Traditional CAR-T cells, while effective against liquid cancers, face challenges
The landscape of cancer research is being transformed by the
For some patients who receive cell therapy such as CAR-T
Using CRISPR screening, the deubiquitinase ATXN3 was identified as a
The approval of yet another RNA-based vaccine for COVID-19 might
L’une des difficultés qui a entravé le succès des cellules
La tendance des cellules CAR-T à perdre leur fonction au